Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Neena Brizmohun
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
New medicines under evaluation at the European Medicines Agency.
The Danish Medicines Agency is testing a new regulatory advice service that medical device SMEs and start-ups anywhere in the world can apply to use.
The Therapeutic Goods Administration is seeking feedback on proposals affecting manufacturers of packages containing therapeutic goods, at least one of which is a medical device or IVD.
The World Health Organization wants to add more tests to the next edition of its Model List of Essential In Vitro Diagnostics.
A major new study showing that the risk of breast cancer in women taking hormone replacement therapy is double previous estimates has prompted UK and EU regulatory agencies and England’s health technology assessment body to look further into the matter.